9969 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.40 |
| 52 Week High | HK$10.96 |
| 52 Week Low | HK$4.22 |
| Beta | 0.96 |
| 1 Month Change | 8.80% |
| 3 Month Change | 64.91% |
| 1 Year Change | 83.24% |
| 3 Year Change | -10.82% |
| 5 Year Change | -42.12% |
| Change since IPO | -4.18% |
Recent News & Updates
Recent updates
What InnoCare Pharma Limited's (HKG:9969) 26% Share Price Gain Is Not Telling You
Apr 22
Advancing Orelabrutinib And Autoimmune Therapies Will Open New Market Opportunities
Mar 23 Orelabrutinib's market position and expansion are set to boost revenue, supported by ongoing clinical advancements and strategic approvals.Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 49% Undervaluation?
Mar 17InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Feb 18Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now
Dec 18Is InnoCare Pharma (HKG:9969) A Risky Investment?
Oct 21Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%
Sep 13Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?
Feb 14Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Oct 06Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
May 11Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?
Apr 11Is InnoCare Pharma (HKG:9969) A Risky Investment?
Jan 25Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Sep 05Shareholder Returns
| 9969 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -1.6% | -6.4% | 2.1% |
| 1Y | 83.2% | 38.8% | 12.6% |
Return vs Industry: 9969 exceeded the Hong Kong Biotechs industry which returned 38.8% over the past year.
Return vs Market: 9969 exceeded the Hong Kong Market which returned 12.6% over the past year.
Price Volatility
| 9969 volatility | |
|---|---|
| 9969 Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 9969's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9969's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 9969 fundamental statistics | |
|---|---|
| Market cap | HK$19.79b |
| Earnings (TTM) | -HK$477.33m |
| Revenue (TTM) | HK$1.09b |
15.1x
P/S Ratio-34.7x
P/E RatioIs 9969 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9969 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.01b |
| Cost of Revenue | CN¥138.44m |
| Gross Profit | CN¥871.01m |
| Other Expenses | CN¥1.31b |
| Earnings | -CN¥440.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 86.29% |
| Net Profit Margin | -43.65% |
| Debt/Equity Ratio | 22.5% |
How did 9969 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 18:43 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnoCare Pharma Limited is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Peng Zou | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |